FDA指南｜开发CAR-T细胞产品的考量（中英文版）.pdfVIP

InternationalBiopharmaIndustry

Organization

国际生物制药产业组织

ConsiderationsfortheDevelopmentofChimericAntigenReceptor(CAR)TCellProducts

开发嵌合抗原受体(CAR)T细胞产品的考量

ConsiderationsfortheDevelopmentof

ChimericAntigenReceptor(CAR)TCell

Products

开发嵌合抗原受体(CAR)T细胞产品的考量

DraftGuidanceforIndustry

行业指南草案

ConsiderationsfortheDevelopmentofChimericAntigenReceptor(CAR)TCellProducts

开发嵌合抗原受体(CAR)T细胞产品的考量

Thisguidancedocumentisforcommentpurposesonly.

本指南仅供评论之用。

Submitonesetofeitherelectronicorwrittencommentsonthisdraftguidancebythedate

providedintheFederalRegisternoticeannouncingtheavailabilityofthedraftguidance.Submit

electroniccommentsto.SubmitwrittencommentstotheDockets

ManagementStaff(HFA-305),FoodandDrugAdministration,5630FishersLane,Rm.1061,

Rockville,MD20852.Youshouldidentifyallcommentswiththedocketnumberlistedinthe

noticeofavailabilitythatpublishesintheFederalRegister.

在《联邦公报》公布指南草案通知中提供的日期之前，可提交关于本指南草案的电子或书

面评论。电子评论可向提交。书面意见可提交给食品和药物管

理局的案卷管理人员(HFA-305)，地址为5630FishersLane,Rm.1061,Rockville,MD20852。

您应该使用联邦公报中发布通知中列出的案卷编号来标识所有评论。

AdditionalcopiesofthisguidanceareavailablefromtheOfficeofCommunication,Outreachand

Development(OCOD),10903NewHampshireAve.,Bldg.71,Rm.3128,SilverSpring,MD

20993-0002,orbycalling1-800-835-4709or240-402-8010,oremailocod@,orfrom

theInternetat/vaccines-blood-biologics/guidance-compliance-regulatory-

information-biologics.

本指南的其他副本可从通讯、外展和发展办公室(OCOD)获取，地址为10903New

HampshireAve.,Bldg.71,Rm.3128,SilverSpring,MD20993-0002，或致电1-800-835-4709

或240-402-8010，或发送电子邮件至ocod@，或通过互联网访问

/vaccines-blood-biologics/guidance-compliance-regulatory-information-

biologics。

Forquestionsonthecontentofthisguidance,contactOCODatthephonenumbersoremail

addresslist